| Literature DB >> 26996316 |
Hyung Eun Lee1, Se Jin Jeon1, Byeol Ryu1, Se Jin Park1, Sang Yoon Ko1, Younghwan Lee1, Eunji Kim1, Sunhee Lee1, Haneul Kim1, Dae Sik Jang2, Jong Hoon Ryu3.
Abstract
Swertisin, a C-glucosylflavone isolated from Swertia japonica, has been known to have anti-inflammatory or antidiabetic activities. Until yet, however, its cognitive function is not investigated. In the present study, we endeavored to elucidate the effects of swertisin on cholinergic blockade-induced memory impairment. Swertisin (5 or 10mg/kg, p.o.) significantly ameliorated scopolamine-induced cognitive impairment in the several behavioral tasks. Also, single administration of swertisin (10mg/kg, p.o.) in normal naïve mice enhanced the latency time in the passive avoidance task. In addition, the ameliorating effect of swertisin on scopolamine-induced memory impairment was significantly antagonized by a sub-effective dose of N6-cyclopentyladenosine (CPA, 0.1mg/kg, i.p). The adenosine A1 receptor antagonistic property of swertisin was confirmed by receptor binding assay. Furthermore, the administration of swertisin significantly increased the phosphorylation levels of hippocampal or cortical protein kinase A (PKA, 5 or 10mg/kg) and CREB (10mg/kg), and co-administration of CPA (0.1mg/kg, i.p) blocked the increased phosphorylated levels of PKA and CREB in the both cortex and hippocampus. Taken together, these results indicate that the memory-ameliorating effects of swertisin may be, in part, mediated through the adenosinergic neurotransmitter system, and that swertisin may be useful for the treatment of cognitive dysfunction observed in several diseases such as Alzheimer's disease.Entities:
Keywords: Adenosine; Alzheimer’s disease; Memory impairment; Swertisin
Mesh:
Substances:
Year: 2016 PMID: 26996316 DOI: 10.1016/j.bbr.2016.03.030
Source DB: PubMed Journal: Behav Brain Res ISSN: 0166-4328 Impact factor: 3.332